Elanco Animal Health [ELAN] vs United Therapeutics [UTHR] Detailed Stock Comparison
Elanco Animal Health
NYSE
Loading...
United Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Elanco Animal Health wins in 5 metrics, United Therapeutics wins in 14 metrics, with 0 ties. United Therapeutics appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Elanco Animal Health | United Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 22.28 | 16.92 | United Therapeutics |
| Price-to-Book Ratio | 1.44 | 2.68 | Elanco Animal Health |
| Debt-to-Equity Ratio | 62.13 | 0.00 | United Therapeutics |
| PEG Ratio | -0.19 | 1.77 | Elanco Animal Health |
| EV/EBITDA | 15.93 | 10.11 | United Therapeutics |
| Profit Margin (TTM) | 9.68% | 40.36% | United Therapeutics |
| Operating Margin (TTM) | 6.85% | 45.64% | United Therapeutics |
| EBITDA Margin (TTM) | 6.85% | 45.64% | United Therapeutics |
| Return on Equity | 6.83% | 19.30% | United Therapeutics |
| Return on Assets (TTM) | 0.98% | 12.96% | United Therapeutics |
| Free Cash Flow (TTM) | $380.00M | $1.08B | United Therapeutics |
| 1-Year Return | 39.63% | 24.59% | Elanco Animal Health |
| Price-to-Sales Ratio (TTM) | 2.17 | 6.37 | Elanco Animal Health |
| Enterprise Value | $13.41B | $16.14B | United Therapeutics |
| EV/Revenue Ratio | 2.99 | 5.24 | Elanco Animal Health |
| Gross Profit Margin (TTM) | 57.45% | 89.03% | United Therapeutics |
| Revenue per Share (TTM) | $9 | $69 | United Therapeutics |
| Earnings per Share (Diluted) | $0.88 | $25.12 | United Therapeutics |
| Beta (Stock Volatility) | 1.62 | 0.62 | United Therapeutics |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Elanco Animal Health vs United Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Elanco Animal Health | -1.59% | 8.19% | 14.68% | 39.06% | 90.06% | 69.88% |
| United Therapeutics | 1.20% | 4.24% | 9.54% | 50.21% | 42.01% | 23.10% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Elanco Animal Health | 39.63% | 66.69% | -38.16% | -39.97% | -39.97% | -39.97% |
| United Therapeutics | 24.59% | 114.46% | 326.34% | 258.80% | 694.13% | 1,312.23% |
News Based Sentiment: Elanco Animal Health vs United Therapeutics
Elanco Animal Health
News based Sentiment: POSITIVE
Elanco experienced a strong month with a new 52-week high, positive earnings results, and upgrades from multiple analysts. The company is also investing in key areas like automation and high-performance computing, signaling a commitment to future growth. While institutional activity is mixed, the overall narrative is positive.
United Therapeutics
News based Sentiment: MIXED
September was a pivotal month for United Therapeutics, marked by the highly positive TETON-2 trial results for Tyvaso in IPF, which drove significant stock gains and analyst upgrades. However, substantial insider selling and ongoing legal battles with Liquidia create a mixed investment picture, requiring careful monitoring of both the opportunities and risks.
Performance & Financial Health Analysis: Elanco Animal Health vs United Therapeutics
| Metric | ELAN | UTHR |
|---|---|---|
| Market Information | ||
| Market Cap | $9.74B | $19.33B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 5,423,590 | 924,001 |
| 90 Day Avg. Volume | 8,718,383 | 904,024 |
| Last Close | $20.47 | $443.44 |
| 52 Week Range | $8.02 - $20.92 | $266.98 - $444.57 |
| % from 52W High | -2.15% | -0.25% |
| All-Time High | $37.61 (Sep 24, 2018) | $444.57 (Oct 02, 2025) |
| % from All-Time High | -45.57% | -0.25% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.12% |
| Quarterly Earnings Growth | 0.05% | 0.11% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | 0.40% |
| Operating Margin (TTM) | 0.07% | 0.46% |
| Return on Equity (TTM) | 0.07% | 0.19% |
| Debt to Equity (MRQ) | 62.13 | 0.00 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $13.64 | $158.65 |
| Cash per Share (MRQ) | $1.09 | $67.41 |
| Operating Cash Flow (TTM) | $572.00M | $1.37B |
| Levered Free Cash Flow (TTM) | $1.21B | $811.05M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Elanco Animal Health vs United Therapeutics
| Metric | ELAN | UTHR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 22.28 | 16.92 |
| Forward P/E | 20.86 | 15.25 |
| PEG Ratio | -0.19 | 1.77 |
| Price to Sales (TTM) | 2.17 | 6.37 |
| Price to Book (MRQ) | 1.44 | 2.68 |
| Market Capitalization | ||
| Market Capitalization | $9.74B | $19.33B |
| Enterprise Value | $13.41B | $16.14B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.99 | 5.24 |
| Enterprise to EBITDA | 15.93 | 10.11 |
| Risk & Other Metrics | ||
| Beta | 1.62 | 0.62 |
| Book Value per Share (MRQ) | $13.64 | $158.65 |
Financial Statements Comparison: Elanco Animal Health vs United Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ELAN | UTHR |
|---|---|---|
| Revenue/Sales | $1.24B | $794.40M |
| Cost of Goods Sold | $528.00M | $92.50M |
| Gross Profit | $713.00M | $701.90M |
| Research & Development | $92.00M | $149.00M |
| Operating Income (EBIT) | $85.00M | $382.80M |
| EBITDA | $243.00M | $449.40M |
| Pre-Tax Income | $25.00M | $423.50M |
| Income Tax | $14.00M | $101.30M |
| Net Income (Profit) | $11.00M | $322.20M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ELAN | UTHR |
|---|---|---|
| Cash & Equivalents | $539.00M | $1.90B |
| Total Current Assets | $3.61B | $3.94B |
| Total Current Liabilities | $1.39B | $721.50M |
| Long-Term Debt | $4.15B | N/A |
| Total Shareholders Equity | $6.78B | $6.81B |
| Retained Earnings | $-1.87B | $7.54B |
| Property, Plant & Equipment | N/A | $0 |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ELAN | UTHR |
|---|---|---|
| Operating Cash Flow | $185.00M | $463.80M |
| Capital Expenditures | $-57.00M | $-74.90M |
| Free Cash Flow | $180.00M | $386.30M |
| Debt Repayment | $-446.00M | $-100.00M |
| Common Stock Repurchase | N/A | $0 |
Short Interest & Institutional Ownership Analysis
| Metric | ELAN | UTHR |
|---|---|---|
| Shares Short | 27.38M | 2.78M |
| Short Ratio | 2.68 | 3.12 |
| Short % of Float | 0.08% | 0.08% |
| Average Daily Volume (10 Day) | 5,423,590 | 924,001 |
| Average Daily Volume (90 Day) | 8,718,383 | 904,024 |
| Shares Outstanding | 494.45M | 44.83M |
| Float Shares | 492.94M | 42.01M |
| % Held by Insiders | 0.01% | 0.02% |
| % Held by Institutions | 1.10% | 1.00% |
Dividend Analysis & Yield Comparison: Elanco Animal Health vs United Therapeutics
| Metric | ELAN | UTHR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |